

Natural History of Progression of HPV Infection to Cervical Lesion or Clearance: Analysis of the Control Arm of the Large, Randomised PATRICIA Study

Unnop Jaisamrarn^{1*}, Xavier Castellsagué², Suzanne M. Garland³, Paulo Naud⁴, Johanna Palmroth⁵, Maria Rowena Del Rosario-Raymundo⁶, Cosette M. Wheeler⁷, Jorge Salmerón⁸, Song-Nan Chow⁹, Dan Apter¹⁰, Julio C. Teixeira¹¹, S. Rachel Skinner^{12,13}, James Hedrick¹⁴, Anne Szarewski^{15†}, Barbara Romanowski¹⁶, Fred Y. Aoki¹⁷, Tino F. Schwarz¹⁸, Willy A. J. Poppe¹⁹, F. Xavier Bosch^{2,20}, Newton S. de Carvalho²¹, Maria Julieta Germar²², Klaus Peters²³, Jorma Paavonen²⁴, Marie-Cecile Bozonnat²⁵, Dominique Descamps²⁶, Frank Struyf²⁶, Gary O. Dubin²⁷, Dominique Rosillon²⁶, Laurence Baril²⁶, HPV PATRICIA Study Group[†]

1 Department of Obstetrics and Gynaecology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, **2** Unit of Infections and Cancer, Cancer Epidemiology Research Program, Institut Català d'Oncologia (ICO), IDIBELL, CIBER-ESP, L'Hospitalet de Llobregat, Catalonia, Spain, **3** Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville/Department of Microbiology, The Royal Children's Hospital, Parkville/Murdoch Childrens Research Institute, Parkville/Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Victoria, Australia, **4** Department of Gynecology & Obstetrics, Federal University of Rio Grande do Sul, UFRGS/HCPA - Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, **5** Central Hospital of North Carelian, Department of Obstetrics and Gynecology, Joensuu, Finland, **6** San Pablo Colleges Medical Center, San Pablo City, Laguna, Philippines, **7** Departments of Pathology and Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States of America, **8** Unidad de Investigación Epidemiológica y en Servicios de Salud, Instituto Mexicano del Seguro Social, Morelos, Mexico, **9** Department of Obstetrics and Gynecology, College of Medicine and the Hospital, National Taiwan University, Taipei, Taiwan, **10** Family Federation of Finland, Sexual Health Clinic, Helsinki, Finland, **11** Departamento de Tocoginecologia da Unicamp, University of Campinas, Campinas, Sao Paulo, Brazil, **12** Vaccines Trials Group, Telethon Institute for Child Health Research, Perth, Western Australia, **13** Sydney University Discipline of Paediatrics and Child Health, Children's Hospital, Westmead, Sydney, New South Wales, Australia, **14** Kentucky Pediatric and Adult Research, Bardstown, Kentucky, United States of America, **15** Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom, **16** Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada, **17** Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada, **18** Central Laboratory and Vaccination Centre, Stiftung Juliusspital, Academic Teaching Hospital of the University of Wuerzburg, Wuerzburg, Germany, **19** Department of Gynaecology, University Hospital KU Leuven Gasthuisberg, Leuven, Belgium, **20** Network on Cooperative Cancer Research, RTICC, Catalonia, Spain, **21** Department of Gynecology and Obstetrics, Federal University of Paraná, Infectious Diseases in Gynecology and Obstetrics Sector, Curitiba, Parana, Brazil, **22** Department of Obstetrics and Gynaecology, University of the Philippines College of Medicine, Philippine General Hospital, Manila, Philippines, **23** Facharzt für Frauenheilkunde und Geburtshilfe, Hamburg, Germany, **24** Department of Obstetrics and Gynaecology, University of Helsinki, Helsinki, Finland, **25** Clinics, Paris, France, **26** GlaxoSmithKline Vaccines, Wavre, Belgium, **27** GlaxoSmithKline Vaccines, King of Prussia, Pennsylvania, United States of America

Abstract

Background: The control arm of PATRICIA (PApillomaTRial against Cancer In young Adults, NCT00122681) was used to investigate the risk of progression from cervical HPV infection to cervical intraepithelial neoplasia (CIN) or clearance of infection, and associated determinants.

Methods and Findings: Women aged 15-25 years were enrolled. A 6-month persistent HPV infection (6MPI) was defined as detection of the same HPV type at two consecutive evaluations over 6 months and clearance as ≥ 2 type-specific HPV negative samples taken at two consecutive intervals of approximately 6 months following a positive sample. The primary endpoint was CIN grade 2 or greater (CIN2+) associated with the same HPV type as a 6MPI. Secondary endpoints were CIN1+/CIN3+ associated with the same HPV type as a 6MPI; CIN1+/CIN2+/CIN3+ associated with an infection of any duration; and clearance of infection. The analyses included 4825 women with 16,785 infections (3363 women with 6902 6MPIs). Risk of developing a CIN1+/CIN2+/CIN3+ associated with same HPV type as a 6MPI varied with HPV type and was significantly higher for oncogenic versus non-oncogenic types. Hazard ratios for development of CIN2+ were 10.44 (95% CI: 6.96-15.65), 9.65 (5.97-15.60), 5.68 (3.50-9.21), 5.38 (2.87-10.06) and 3.87 (2.38-6.30) for HPV-16, HPV-33, HPV-31, HPV-45 and HPV-18, respectively. HPV-16 or HPV-33 6MPIs had ~25-fold higher risk for progression to CIN3+. Previous or concomitant HPV infection or CIN1+ associated with a different HPV type increased risk. Of the different oncogenic HPV types, HPV-16 and HPV-31 infections were least likely to clear.

Conclusions: Cervical infections with oncogenic HPV types increased the risk of CIN2+ and CIN3+. Previous or concomitant infection or CIN1+ also increased the risk. HPV-16 and HPV-33 have by far the highest risk of progression to CIN3+, and HPV-16 and HPV-31 have the lowest chance of clearance.

Citation: Jaisamrarn U, Castellsagué X, Garland SM, Naud P, Palmroth J, et al. (2013) Natural History of Progression of HPV Infection to Cervical Lesion or Clearance: Analysis of the Control Arm of the Large, Randomised PATRICIA Study. *PLoS ONE* 8(11): e79260. doi:10.1371/journal.pone.0079260

Editor: D William Cameron, University of Ottawa, Canada

Received: April 2, 2013; **Accepted:** July 25, 2013; **Published:** November 19, 2013

Copyright: © 2013 Jaisamrarn et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The study (NCT00122681) was funded by GlaxoSmithKline Biologicals SA, who designed the trial in collaboration with investigators. The costs related to the collection of data from this study, together with the development of this manuscript, were funded and coordinated by GlaxoSmithKline Biologicals SA. All authors contributed to the development of the manuscript and approved the manuscript for publication. The corresponding author (UJ) and the core writing team (UJ, XC, SMG, MRDRR, PN, JP (Johanna Palmroth), LB, DR) had the final responsibility for the decision to submit for publication. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have the following interests: DD, GD, LB, FS and DR are paid employees of the GlaxoSmithKline group of companies, the funder of this study. DD, DR, GD, LB and FS own stocks in GlaxoSmithKline Biologicals SA, and GD receives royalties from Wyeth Vaccines. SMG owns stock in CSL Ltd. AS, MRDRR, SMG, UJ, XC have received grants/funding through their institutions to do research for GlaxoSmithKline Biologicals SA. JP has received grants/funding through their institutions to do research for GlaxoSmithKline Biologicals SA and Merck Sharp & Dohme. FXB has received, via his institutions, educational grants from GlaxoSmithKline Biologicals SA and Merck Sharp & Dohme, Sanofi Pasteur MSD; JH has received grants through his institution by Kentucky Pediatric and Adult Res. DA has received grants through his institution by VL-Medi, Väestöliitto. CMW, JCT and SRS have received grants/have grants pending from GlaxoSmithKline Biologicals SA and Merck Sharp & Dohme, and XC from Sanofi Pasteur MSD. SMG and SRS have received grants/have grants pending from CSL Ltd; JS has received grants from Qiagen; CMW has received reagents and equipment through the University of New Mexico for HPV genotyping from Roche Molecular Systems. MCB, SMG and TFS have received consulting fees from GlaxoSmithKline Biologicals SA; AS, XC have received consulting fees or honoraria from GlaxoSmithKline Biologicals SA and Merck Sharp & Dohme, and XC from Sanofi Pasteur MSD; MRDRR, have received honoraria from GlaxoSmithKline Biologicals SA; FYA, JCT, SMG, SRS and TFS have received payment for board membership by GlaxoSmithKline Biologicals SA; WAJP has received payment, via his institution for board membership, consultancy and expert testimony; AS, FYA, JCT, MJG, NSC, SMG, TFS, WAJP and XC have received payment for lectures including service on speakers bureau; AS, FYA, SMG and TFS have received payment for the development of educational presentations; AS, CMW, FYA, JCT, JH, MJG, MRDRR, SMG, SRS, UJ and XC have received travel reimbursements from GlaxoSmithKline Biologicals SA. DA has received travel reimbursements from VL-Medi. FXB and XC have received travel reimbursement from Merck Sharp & Dohme, Sanofi Pasteur MSD. NSDC has received travel reimbursement from IPAMICover DTG. J Palmroth has been invited to international gynecological cancer congresses by Merck Sharp & Dohme, Sanofi Pasteur MSD and Roche who sponsored congress fees and travel costs. BR has received payment for consultancy, payment for lectures including service on speakers bureau and support for travel via her institution by B Romanowski Prof Corporation. FXB has received support for travel and honorarium for speaking at meeting organized by GlaxoSmithKline Biologicals SA, Merck Sharp & Dohme, Sanofi Pasteur MSD. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors. Dr. Szarewski passed away prior to the publication of the paper. The corresponding author, Unnop Jaisamrarn, has supplied the information regarding her contributions to the manuscript and her competing interests and they are correct to the best of his knowledge.

* E-mail: Unnop.J@Chula.ac.th

¶ Membership of the HPV PATRICIA Study Group is provided in the Acknowledgments.

† Deceased.

Introduction

Persistent infection with oncogenic human papillomavirus (HPV) is necessary for the development of cervical cancer [1]. Approximately 15 oncogenic HPV types have been identified to date, of which HPV-16 and HPV-18 are the most prevalent in cervical cancer, accounting for approximately 70% of cases worldwide [2].

Many sexually active individuals become infected with HPV after beginning their first sexual relationship [3]. HPV infections are usually transient, and even those that persist for a few months are usually cleared naturally. Development of cervical intraepithelial neoplasia (CIN) and cervical cancer is almost always preceded by a persistent oncogenic HPV infection [4,5]. Numerous determinants are thought to affect progression of HPV infection to a CIN, including behavioural determinants such as tobacco exposure, sexual intercourse with increased numbers of partners, contraceptive use and previous pregnancy [6–8], as well as immunosuppression and presence of infections with other sexually-transmitted pathogens such as *Chlamydia trachomatis* and herpes simplex virus [9–11]. CIN is diagnosed from histological analysis of a cervical lesion. It is categorised into three grades: CIN grade 1 (CIN1), grade 2

(CIN2) and grade 3 (CIN3) with CIN3 considered as the immediate precursor to invasive cervical cancer (ICC) [12].

A better understanding is needed of the natural history of progression of a cervical HPV infection to a CIN or to clearance of the infection. Such analyses can be performed using the control arm of large trials of prophylactic HPV vaccines where data on HPV types, histological lesions and potential determinants of disease progression are extensively collected. The present paper reports the analysis of HPV infection and its clearance or progression to CIN in the PapiIoma Trial against Cancer In young Adults (PATRICIA), a phase III trial of the HPV-16/18 AS04-adjuvanted vaccine (*Cervarix*®) in over 18,000 young women.

Methods

This analysis was based on data obtained from the control arm of the double-blind, randomised, multinational (14 countries), controlled, 4-year PATRICIA trial (NCT00122681/580299/008). The objectives were to investigate the time between detection of an HPV infection (through HPV genotyping) and development of a CIN lesion associated with the same HPV type, and to evaluate

determinants associated with disease progression or natural clearance of infection.

Study population and procedures

The clinical trial methodology, including full inclusion and exclusion criteria, trial locations and dates, has been described previously [13,14]. Briefly, women aged 15–25 years with no more than 6 lifetime sexual partners were enrolled in the study and were randomised to HPV-16/18 AS04-adjuvanted vaccine or control hepatitis A vaccine. HPV genotyping of cervical liquid-based cytology samples was performed at baseline and every 6 months throughout the 4-year study by polymerase chain reaction (PCR). Cytological examination using the Bethesda system was performed every 12 months and, when a biopsy was performed by the physician, histological classification was done. Oncogenic HPV types tested for were HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68; non-oncogenic types tested for were HPV-6, 11, 34, 40, 42, 43, 44, 53, 54, 70 and 74 [15].

Subjects completed a behavioural questionnaire [16] including tobacco exposure, sexual intercourse and contraceptive use at the second study visit, 1 month after the first vaccination, and yearly during the follow-up period. For the purpose of this analysis, the term sexual intercourse included penetrative, non-penetrative genital-to-genital, or oral-genital sexual contact.

Written informed consent or assent was obtained from all participants or their parents, and the protocol and other materials were approved by independent ethics committees or institutional review boards (Table S1 in File S1).

Endpoint definitions

HPV infections were classified according to their duration as a transient infection, a 6-month persistent infection (6MPI), a 12-month persistent infection (12MPI), a less than 6MPI, and an infection detected only at the last visit of the study. A transient infection was defined as detection of a specific HPV type in a cervical sample at any single point during the follow-up period, followed by a negative sample for the same HPV type at the next evaluation. A 6MPI was defined as detection of the same HPV type at two consecutive evaluations over a 6-month period or greater i.e. a sequence of positive samples with the same HPV type not interrupted by negative samples over a total range of >5 months (>150 days). The start of the 6MPI was defined as the date of the first positive sample in the sequence. A 12MPI was defined in the same way, over a 12-month period. A less than 6MPI was defined as an infection with duration ≤ 150 days, again with the same HPV type, not interrupted by negative samples (although visits were scheduled for every 6 months, in some cases there was less time between consecutive visits, allowing a category of persistent HPV infection of less than 6 months' duration).

Clearance was defined as the occurrence of at least two consecutive type-specific negative HPV DNA samples taken at approximately a 6-month interval following a positive sample. Although we recognise that apparent clearance could in reality be an inability to detect the infection, we use the term clearance for convenience.

Histologically confirmed lesions were detected in colposcopically-directed biopsy samples or post-excision samples following treatment and were categorised as CIN grade 1 or greater (CIN1+), CIN grade 2 or greater (CIN2+) and CIN grade 3 or greater (CIN3+). CIN1+ included CIN1, CIN2, CIN3 and adenocarcinoma in situ (AIS) identified by standard methods.

Statistical analysis

The primary endpoint was CIN2+ associated with the same HPV type as a 6MPI. Secondary endpoints were CIN1+ and CIN3+ associated with the same HPV type as a 6MPI; CIN1+, CIN2+ and CIN3+ associated with the same HPV type as an infection of any duration; and clearance of HPV infections.

Analysis cohort. The analysis was performed in the control group of the total vaccinated cohort for efficacy (TVC-E) (Figure 1). The TVC-E included all women who received at least one dose of control vaccine and had normal or low-grade cytology at baseline (ie, negative, atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion). The analysis population included only women aged 15–25 years and only those in whom at least one cervical HPV infection was detected during the study. Infections in participants in whom HPV DNA was detected at baseline but not at month 6 were classified as transient for the purpose of the analysis. However, it must be noted that these could have been persistent infections because the date of their origin was unknown.

Determinants. The main determinants of interest were HPV type and duration of HPV infection. Covariates known to influence the risk of acquiring HPV infection were also accounted for in the analyses. Eight potential behavioural characteristics were included in the models: tobacco exposure measured as number of pack-years (one pack-year was equivalent to 365 packs of cigarettes), age at first sexual intercourse, number of sexual partners during the past 12 months, history of *Chlamydia trachomatis* during the past 12 months, marital/partner status, previous pregnancy, use of hormones for contraception or other indication, and use of an intrauterine device.

In addition, the models accounted for previous cervical HPV infection with an oncogenic HPV type or with only non-oncogenic HPV types (i.e. preceding the onset of the reference infection), cervical HPV co-infection with an oncogenic HPV type or with only non-oncogenic HPV types (i.e. following the onset of the reference infection and preceding detection of the lesion), previous CIN1+ lesion associated with any oncogenic or non-oncogenic HPV type different to the reference infection (i.e. CIN1+ preceding the onset of the reference infection), and concomitant CIN1+ lesion associated with any oncogenic or non-oncogenic HPV type different to the reference infection (i.e. CIN1+ following the onset of the reference infection and preceding its end). Cervical HPV co-infections and CIN1+ lesions associated with an HPV type different to the reference HPV infection were included in the models as time-varying covariates.

General statistical considerations. The time between a cervical HPV infection and development of a CIN lesion was




Figure 1. Subject disposition. From the 9337 women enrolled in the control arm of the PATRICIA trial, 4512 were excluded from the present analyses including 4431 subjects with no cervical HPV infection detected during the 48 months of follow-up. 4825 women representing 16785 cervical HPV infections (blue) were included and two sub-cohorts were constituted: women with a 6-month persistent HPV infection (6MPI) (n = 3363 representing 6902 infections) (light blue) and women with a natural clearance of the HPV infection (n = 4011 representing 10983 clearances) (light purple). The numbers of women and of CIN1+/CIN2+/CIN3+ lesions were calculated after exclusion of the lesions occurring after 48 months for any duration of HPV infection (blue) and for 6MPI (light blue).

Among the 119 subjects with 6MPI and CIN3+, 9 had AIS (11 episodes). Among the 124 subjects with an infection of any duration and CIN3+, 10 had AIS (13 episodes). No invasive cervical cancer was found.

6MPI: 6-month persistent infection; CIN: cervical intraepithelial neoplasia; HPV: human papillomavirus; TVC-E: total vaccinated cohort for efficacy.

doi: 10.1371/journal.pone.0079260.g001

analysed using the Kaplan-Meier method as well as univariate and multivariable Cox regression models. The statistical unit was the infection, and variance estimates adjusted for the correlation within subjects were obtained using the robust estimation method [17,18]. The same methods were used to analyse natural clearance of HPV infection. All data were censored at the last recorded visit or at 48 months, whichever occurred first. Covariates with a p-value <0.2 in the univariate model were included in the multivariable model, with the exception of region which was always included regardless of the p-value obtained. Infections or lesions with a missing value for a covariate included in the analysis were excluded from the multivariable analysis. All analyses were performed using SAS version 9.2.

Results

Subject disposition and characteristics

A total of 9256 women in the TVC-E were aged 15–25 years and had negative or low-grade cytology (Figure 1). Of these, subjects with no cervical HPV infection during the study (n=3794, 41.0%) or in whom an infection was detected only at the last visit of the study (n=637, 6.9%) were excluded from the analysis (Figure 1). A total of 4825 women with at least one

cervical HPV infection of any duration (16,785 infections) during the 48 month follow-up were included. Of these, 3363 women had at least one 6MPI (6902 infections), 2283 had a 12MPI (3487 infections), 355 had persistent HPV infection(s) of less than 6 months (449 infections), and 3945 had transient HPV infection(s) (9434 infections). A total of 1285 women had an infection detected at baseline but not at month 6 (classed as a transient infection for the purpose of the analysis, although its duration prior to study entry was unknown). The five most prevalent HPV types were HPV-16 (9.3% of any infections and 13.9% of 6MPIs), HPV-18 (5.6% and 6.0%), HPV-31 (5.4% and 6.5%), HPV-33 (2.9% and 3.0%) and HPV-45 (2.3% and 2.2%). The prevalence of other oncogenic HPV types was 45.7% (any infection) and 47.4% (6MPI), and the prevalence of non-oncogenic types was 28.7% (any infection) and 20.9% (6MPI).

Among the subjects with at least one cervical HPV infection of any duration, mean (SD) age was 19.7 (3.1) years, most were single (74.4%), with no tobacco exposure (63.4%), had started sexual intercourse between the ages of 15 and 17 years (51.8%), had one or no sexual partner during the past 12 months (71.3%), had not been pregnant (73.1%), had no history of *Chlamydia trachomatis* (90.3%) and had used

Table 1. Frequency distribution of age, region and other determinants at baseline according to duration of cervical HPV infection.

Determinant	Category	6MPI	HPV infection (any duration)
		N=3363	N=4825
Age (years)	Mean (SD)	19.5 (3.0)	19.7 (3.1)
	Median (range)	19 (15–25)	19 (15–25)
Age group, n (%)	15–17 years	1322 (39.3)	1753 (36.3)
	18–25 years	2041 (60.7)	3072 (63.7)
Region, n (%)	Europe	1422 (42.3)	1874 (38.8)
	Asia Pacific	767 (22.8)	1229 (25.5)
	North America	568 (16.9)	857 (17.8)
	Latin America	606 (18.0)	865 (17.9)
Marital/partner status, n (%)	Single	2595 (77.2)	3591 (74.4)
	Living or lived with partner ²	733 (21.8)	1178 (24.4)
	Missing	35 (1.0)	56 (1.2)
Tobacco exposure (number of pack-years), n (%)	None or less than 6 months (<0.5)	2031 (60.4)	3058 (63.4)
	At least 6 months (≥0.5)	1296 (38.5)	1713 (35.5)
	Missing	36 (1.1)	54 (1.1)
Age at first sexual intercourse, n (%)	Never had sexual intercourse	3 (0.1)	26 (0.5)
	≥26	3 (0.1)	6 (0.1)
	18–25	996 (29.6)	1525 (31.6)
	15–17 years	1790 (53.2)	2497 (51.8)
	<15 years	569 (16.9)	763 (15.8)
Number of sexual partners during the past 12 months, n (%)	Missing	2 (0.1)	8 (0.2)
	0–1	2294 (68.2)	3441 (71.3)
	2–3	869 (25.8)	1132 (23.5)
	≥4	193 (5.7)	238 (4.9)
Previous pregnancy, n (%)	Missing	7 (0.2)	14 (0.3)
	Yes	817 (24.3)	1281 (26.6)
	No	2539 (75.5)	3527 (73.1)
At least one delivery, n (%)	Missing	7 (0.2)	17 (0.4)
	Yes	516 (15.3)	814 (16.9)
	No	2837 (84.4)	3991 (82.7)
History of <i>Chlamydia trachomatis</i> during the past 12 months, n (%)	Missing	10 (0.3)	20 (0.4)
	Yes	344 (10.2)	468 (9.7)
	No	3018 (89.7)	4355 (90.3)
Contraceptive use [1], n (%)	Missing	1 (0.03)	2 (0.04)
	Abstinent or no contraception	1032 (30.7)	1535 (31.8)
	Hormonal	2253 (67.0)	3155 (65.4)
	Intra-uterine device	146 (4.3)	221 (4.6)
History of sexual intercourse at study entry	Sterilised	25 (0.7)	38 (0.8)
	Yes	3114 (92.6)	4426 (91.7)
	No	242 (7.2)	385 (8.0)
History of sexual intercourse at the end of the study	Missing	7 (0.2)	14 (0.3)
	Yes	3359 (99.9)	4798 (99.4)
	No	3 (0.1)	26 (0.5)
	Missing	1 (0.03)	1 (0.02)

¹ Women could be using more than one method of contraception.

² Living with or had lived with partner included married, living with partner, widowed, divorced, separated.

6MPI: 6-month persistent infection; HPV: human papillomavirus

doi: 10.1371/journal.pone.0079260.t001

hormonal contraception (65.4%) (Table 1). Characteristics of subjects in whom at least one 6MPI was detected were similar.

Risk of Developing a CIN Lesion Associated with a 6-Month Persistent Infection

The number of women with a 6MPI who developed a CIN1+, CIN2+ or CIN3+ lesion during the study is shown in Figure 1. Lesions that developed after Month 48 were not included in the analysis. The multivariable analysis showed that, for women with a 6MPI, the cumulative risk of developing a CIN1+, CIN2+ or CIN3+ lesion associated with the same HPV type significantly increased for an infection with the five most prevalent HPV types (HPV-16/18/31/33/45) or with any other oncogenic type compared with a non-oncogenic HPV type (Table 2; Figures 2a and 2b). Compared with women with a non-oncogenic HPV 6MPI, women with HPV-16 or HPV-33 6MPIs had approximately a 25-fold higher risk for progression to a CIN3+ lesion, those with a HPV-31 6MPI had a 10-fold higher risk, those with HPV-18 and HPV-45 6MPIs had a 6-fold higher risk, and those with 6MPIs with any other oncogenic type had a 4-fold higher risk. The association between a 6MPI with an oncogenic HPV type and development of a lesion became stronger as lesion severity increased; for example, the Hazard Ratio (HR) from the multivariable analysis for HPV-16 increased from 4.60 for CIN1+ to 10.44 for CIN2+ and to 26.82 for CIN3+.

A previous infection with an oncogenic HPV type different from the 6MPI significantly increased the risk of CIN1+ (previous infection was not included in the multivariable analysis for CIN2+ and CIN3+ because a p-value of >0.2 was obtained in the univariate analysis) (Table 2). Presence of a co-infection with a different oncogenic HPV type also significantly increased the risk of developing CIN1+ or CIN2+, but not CIN3+ (Table 2). A CIN1+ lesion associated with a different oncogenic HPV type also significantly increased the risk of CIN1+, CIN2+ or CIN3+, regardless of whether it occurred prior to or concomitant with the 6MPI.

Results of the univariate and multivariable analyses of the risk of developing a CIN lesion that account for behavioural determinants are shown in Tables S2–S4 in File S1. Behavioural determinants that were significant ($p < 0.05$) in the multivariable analysis were tobacco exposure and previous pregnancy for CIN1+, previous pregnancy and use of hormones for contraception or other indication for CIN2+, and previous pregnancy and age at first sexual intercourse for CIN3+.

Risk of developing a CIN lesion associated with an HPV infection of any duration

HPV-16, HPV-51 and HPV-52 were the most frequent HPV types observed (1557, 1613 and 1374 infections, respectively), with HPV-16 being the most frequently detected in CIN1+ and CIN2+. As observed for 6MPIs, in the multivariable analysis, the association between an infection of any duration with an oncogenic HPV type and development of a lesion became stronger as lesion severity increased (Table 3). Again, the risk of developing a CIN lesion associated with the same HPV type was higher for HPV-16, HPV-33, HPV-31, HPV-18 and HPV-45, any other oncogenic HPV type compared with non-oncogenic HPV types; the highest risk was for HPV-16 and

HPV-33 (approximately 20-fold), followed by HPV-31 (8-fold), and then by HPV-18 or HPV-45 (4.5-fold) (Table 3).

The duration of the HPV infection had a marked impact on the risk of developing a lesion, with a 6MPI showing the highest risk for CIN lesion development, followed by a persistent infection of less than 6 months duration, while a transient HPV infection showed the lowest risk (Table 3). Compared with a transient infection, both persistent infections of less than 6 months duration and 6MPIs were significantly associated with higher risk of CIN1+ (HR: 2.48 and 4.25, respectively) and CIN2+ (HR: 2.32 and 4.61, respectively); only 6MPI was significantly associated with increased risk of CIN3+ (HR: 5.29).

Co-infection with an oncogenic HPV type different from the reference infection significantly increased the risk of developing CIN1+, CIN2+ or CIN3+ (Table 3). A previous infection with a different oncogenic HPV type also increased the risk of CIN1+ and CIN2+ (the analysis was not performed for CIN3+ because this covariate was not statistically significant ($p > 0.2$) in the univariate model). A previous or concomitant CIN1+ lesion associated with a different oncogenic HPV type also significantly increased the risk of lesion development.

Results of the univariate and multivariable analyses of the risk of developing a CIN lesion that account for behavioural determinants are shown in Tables S5–S7 in File S1. Behavioural determinants that were significant ($p < 0.05$) in the multivariable analysis were tobacco exposure and previous pregnancy for CIN1+, previous pregnancy and use of hormones for contraception or other indication for CIN2+, and previous pregnancy for CIN3+.

Clearance of HPV infection

Overall, 53%, 79%, 87% and 89% of all HPV infections were cleared at 12, 24, 36 and 48 months, respectively (Figure 3a). The median time to clearance for transient HPV infections and 6MPIs was 6.26 months and 18.85 months, respectively (Table 4). HPV-16 and HPV-31 were significantly less likely to clear than a non-oncogenic HPV type, and other oncogenic HPV types had an intermediate chance of clearance (Figure 3b; Table 4). Previous infection with the same or with other HPV types reduced the chance of clearance; in contrast, the chance of clearance was increased by co-infection with another oncogenic HPV type in this analysis.

Results of the univariate and multivariable analyses of clearance of HPV infection that account for behavioural determinants are shown in Table S8 in File S1. Determinants that were significant ($p < 0.05$) in the multivariable analysis were region and marital status (the chance of clearance was lower in women who were living or had lived with a partner than in single women).

The results for prevalence, risk of progression to CIN and chance of clearance are summarised according to HPV type in Figure 4. HPV-16 has a high prevalence, high risk of progression and low chance of clearance, and is thus overall the most high-risk HPV type. HPV-33 shows a lower prevalence, a high risk of progression and a medium chance of clearance. HPV-31 has a medium prevalence, a medium risk of progression and a low chance of clearance. HPV-18 has a

Table 2. Multivariable analysis of the risk of progression of a 6MPI infection to a CIN lesion associated with the same HPV type.

	CIN1+		CIN2+		CIN3+	
	Hazard ratio ¹ (95% CI)	p-value	Hazard ratio ¹ (95% CI)	p-value	Hazard ratio ¹ (95% CI)	p-value
	6835 infections in 3337 women		6835 infections in 3337 women		6785 infections in 3325 women	
	818 lesions ²		464 lesions ²		152 lesions ²	
HPV type						
Non-oncogenic type	1	-	1	-	1	-
HPV-16	4.60 (3.47–6.09)	<0.0001	10.44 (6.96–15.65)	<0.0001	26.82 (10.00–71.94)	<0.0001
HPV-18	2.43 (1.70–3.48)	<0.0001	3.87 (2.38–6.30)	<0.0001	6.04 (1.82–20.04)	0.0033
HPV-31	3.33 (2.39–4.64)	<0.0001	5.68 (3.50–9.21)	<0.0001	9.80 (3.16–30.37)	<0.0001
HPV-33	4.44 (3.12–6.32)	<0.0001	9.65 (5.97–15.60)	<0.0001	25.04 (9.00–69.69)	<0.0001
HPV-45	2.53 (1.53–4.17)	0.0003	5.38 (2.87–10.06)	<0.0001	6.88 (1.54–30.74)	0.0116
Other oncogenic type	2.16 (1.66–2.81)	<0.0001	2.80 (1.87–4.19)	<0.0001	3.73 (1.34–10.37)	0.0117
	<i><0.0001</i>		<i><0.0001</i>		<i><0.0001</i>	
Previous cervical HPV infection³						
No	1	-	Not included		Not included	
Yes (at least 1 oncogenic HPV type)	1.32 (1.11–1.56)	0.0016				
Yes (only non-oncogenic HPV types)	1.15 (0.78–1.70)	0.4846				
	<i>0.0071</i>					
Cervical HPV co-infection^{4,5}						
No	1	-	1	-	1	-
Yes (at least 1 oncogenic HPV type)	1.75 (1.44–2.12)	<0.0001	1.88 (1.46–2.41)	<0.0001	1.36 (0.94–1.98)	0.1018
Yes (only non-oncogenic HPV types)	1.05 (0.76–1.46)	0.7689	0.80 (0.49–1.31)	0.3731	0.74 (0.33–1.66)	0.4657
	<i><0.0001</i>		<i><0.0001</i>		<i>0.0955</i>	
Previous CIN1+⁶						
No	1	-	1	-	1	-
Yes (at least 1 oncogenic HPV type)	1.94 (1.21–3.12)	0.0059	2.75 (1.58–4.80)	0.0004	3.78 (1.69–8.41)	0.0012
Yes (only non-oncogenic HPV types)	-		-		-	
	<i>0.0059</i>		<i>0.0004</i>		<i>0.0012</i>	
Concomitant CIN1+^{5,7}						
No	1	-	1	-	1	-
Yes (any oncogenic or non-oncogenic HPV type)	2.27 (1.67–3.08)	<0.0001	2.03 (1.40–2.93)	0.0002	3.86 (2.31–6.47)	<0.0001
	<i><0.0001</i>		<i>0.0002</i>		<i><0.0001</i>	

¹ Covariates were included in the multivariable analysis if they had a global p-value of <0.2 in the univariate analysis (except region which was always included); covariates were: region, smoking, age at first sexual intercourse, number of sexual partners during the past 12 months, history of Chlamydia trachomatis during the past 12 months, marital/partner status, previous pregnancy, use of hormones for contraception or other indication, use of intrauterine device, previous or concomitant HPV co-infections, previous or concomitant CIN1+. Refer to Tables S2–S4 for more detail.

² Infections or lesions with a missing value for a covariate included in the analysis were excluded from the multivariable analysis.

³ Preceding the onset of the reference infection.

⁴ Following the onset of the reference infection and preceding detection of the lesion.

⁵ Time-varying covariate.

⁶ CIN1+ associated with an HPV type different to the reference infection, preceding the onset of the 6MPI.

⁷ CIN1+ associated with an HPV type different to the reference infection, concomitant to the 6MPI (following its onset and preceding its end).

Values in italics show the global p-value.

6MPI: 6-month persistent infection; CIN: cervical intraepithelial neoplasia; HPV: human papillomavirus

doi: 10.1371/journal.pone.0079260.t002

consistently medium prevalence, progression and clearance. Findings for the other HPV types are less consistent.

Discussion

The analysis evaluated the risk of progression to CIN lesion and the chance of clearance according to HPV type. The role

of HPV types and persistent infection as the main risk factors for CIN lesion were confirmed and the results also showed the roles of previous infection and co-infection with an oncogenic HPV type, as well as previous or concomitant CIN1+, as risk factors for progression to CIN in young women. Our large sample size allowed for the first time calculation of the risk of progression of HPV infection to CIN3+. Previous studies have




Figure 2. Risk of progression of a 6MPI to CIN2+ or CIN3+ associated with the same HPV type. 2a. CIN2+ 2b. CIN3+

Kaplan–Meier Estimates of Cumulative Risk (%) of Developing CIN2+ Lesions (Figure 2a) or CIN3+ Lesions (Figure 2b) Associated with the Same HPV Type Were Calculated for HPV-16, HPV-18, HPV-31, HPV-33, HPV-45, Other Oncogenic HPV Types and Non-Oncogenic HPV Types

doi: 10.1371/journal.pone.0079260.g002

been limited in their sample size and number of infections evaluated, and largely focused on development of invasive cervical cancer in adult women.

The five most prevalent HPV types were HPV-16, HPV-31, HPV-18, HPV-33 and HPV-45. The risk of developing a CIN lesion was higher following infection with oncogenic HPV types than with non-oncogenic types, the highest risk being with

HPV-16 and HPV-33 (up to 10-fold higher for CIN2+ and up to 25-fold higher for CIN3+ compared with non-oncogenic types), followed by HPV-31, HPV-45 and HPV-18. The association between an infection with an oncogenic HPV type and the risk of CIN became stronger as lesion severity increased, reflecting the increasing prevalence of HPV types belonging to the A7 and A9 HPV species as lesion severity increases (the A7

Table 3. Multivariable analysis of the risk of progression of an HPV infection of any duration to a CIN lesion associated with the same HPV type.

	CIN1+		CIN2+		CIN3+	
	Hazard ratio ¹ (95% CI)	p-value	Hazard ratio ¹ (95% CI)	p-value	Hazard ratio ¹ (95% CI)	p-value
	16580 infections in 4789 Women		16580 infections in 4789 women		16596 infections in 4791 women	
	1069 lesions ²		577 lesions ²		180 lesions ²	
HPV type						
Non-oncogenic type	1	-	1	-	1	-
HPV-16	4.39 (3.52–5.47)	<0.0001	9.25 (6.84–12.51)	<0.0001	20.93 (9.97–43.95)	<0.0001
HPV-18	2.47 (1.85–3.30)	<0.0001	3.56 (2.40–5.27)	<0.0001	4.74 (1.78–12.58)	0.0018
HPV-31	3.34 (2.57–4.34)	<0.0001	5.09 (3.56–7.29)	<0.0001	7.82 (3.46–17.63)	<0.0001
HPV-33	4.36 (3.29–5.79)	<0.0001	9.14 (6.34–13.18)	<0.0001	20.47 (9.45–44.35)	<0.0001
HPV-45	2.28 (1.49–3.49)	0.0002	3.64 (2.08–6.40)	<0.0001	4.45 (1.17–16.97)	0.0286
Other oncogenic type	2.19 (1.79–2.67)	<0.0001	2.63 (1.94–3.57)	<0.0001	3.51 (1.62–7.59)	0.0014
	<0.0001		<0.0001		<0.0001	
Duration of infection						
Transient	1	-	1	-	1	-
Less than 6MPI	2.48 (1.54–3.98)	0.0002	2.32 (1.22–4.40)	0.0102	1.45 (0.32–6.48)	0.6275
6MPI	4.25 (3.63–4.97)	<0.0001	4.61 (3.66–5.81)	<0.0001	5.29 (3.34–8.38)	<0.0001
	<0.0001		<0.0001		<0.0001	
Previous cervical HPV infection³						
No	1	-	1	-	Not included	
Yes (at least 1 oncogenic HPV type)	1.52 (1.31–1.77)	<0.0001	1.27 (1.03–1.57)	0.0254		
Yes (only non-oncogenic HPV types)	1.22 (0.85–1.73)	0.2791	1.21 (0.75–1.96)	0.4324		
	<0.0001		0.0803			
Cervical HPV co-infections^{4,5}						
No	1	-	1	-	1	-
Yes (at least 1 oncogenic HPV type)	1.85 (1.54–2.21)	<0.0001	1.93 (1.52–2.45)	<0.0001	1.40 (0.99–1.99)	0.0595
Yes (only non-oncogenic HPV types)	0.99 (0.73–1.34)	0.9366	0.76 (0.48–1.20)	0.2375	0.60 (0.27–1.33)	0.2110
	<0.0001		<0.0001		0.0243	
Previous CIN1+⁶						
No	1	-	1	-	1	-
Yes (any oncogenic or non-oncogenic HPV type)	2.32 (1.59–3.40)	<0.0001	2.74 (1.73–4.32)	<0.0001	3.65 (1.76–7.54)	0.0005
	<0.0001		<0.0001		0.0005	
Concomitant CIN1+^{5,7}						
No	1	-	1	-	1	-
Yes (any oncogenic or non-oncogenic HPV type)	2.76 (2.10–3.63)	<0.0001	2.65 (1.89–3.71)	<0.0001	4.70 (2.77–7.99)	<0.0001
	<0.0001		<0.0001		<0.0001	

¹ Covariates were included in the multivariable analysis if they had a global p-value of <0.2 in the univariate analysis (except region which was always included); covariates were: region, smoking, age at first sexual intercourse, number of sexual partners during the past 12 months, history of Chlamydia trachomatis during the past 12 months, marital/partner status, previous pregnancy, use of hormones for contraception or other indication, use of intrauterine device, previous or concomitant HPV co-infections, previous or concomitant CIN1+. Refer to Tables S5–S7 for more detail.

² Infections or lesions with a missing value for a covariate included in the analysis were excluded from the multivariable analysis.

³ Preceding the onset of the reference infection.

⁴ Following the onset of the reference infection and preceding detection of the lesion.

⁵ Time-varying covariate.

⁶ CIN1+ associated with an HPV type different to the reference infection, preceding the onset of the 6MPI.

⁷ CIN1+ associated with an HPV type different to the reference, concomitant to the 6MPI (following its onset and preceding its end).

Values in italics show the global p-value.

6MPI: 6-month persistent infection; CIN: cervical intraepithelial neoplasia; HPV: human papillomavirus

doi: 10.1371/journal.pone.0079260.t003

species includes HPV-18 and HPV-45, while the A9 species includes HPV-16, HPV-31 and HPV-33).

Our findings reflect those of other studies evaluating prevalence of different HPV types in cervical cancer and the risk of progression from infection to pre-cancerous lesions or




Figure 3. Cumulative chance of clearing a cervical HPV infection (prevalent and incident infections). 3a. Duration of infection

3b. HPV type (infection of any duration)

Kaplan–Meier estimates of probability of clearance (%) were calculated for transient, less than 6-month persistent HPV infection (6MPI), 6MPI and overall (Figure 3a) or according the HPV types (Figure 3b): HPV-16, HPV-18, HPV-31, HPV-33, HPV-45, other oncogenic HPV types and non-oncogenic HPV types.

doi: 10.1371/journal.pone.0079260.g003

cancer. A US-based case-control study showed that the most prevalent HPV types in ICC and carcinoma in situ are HPV-16/18/45 and HPV-16/31/33, respectively [19]. An international cross-sectional study of HPV genotype attribution confirmed that the most prevalent oncogenic HPV types in ICC are HPV-16/18/31/33/35/45/52/58 [2]. Schiffman and

colleagues have hypothesised that infections with HPV-16 are most likely to persist and progress to pre-cancerous and cancerous lesions [20]. A population-based screening programme has shown that the risk of progression to CIN2+ is similar for women infected by HPV-16 and HPV-33 [21]. Similarly, more recent data from the control arm of the

Table 4. Multivariable analysis of the median time to clearance of cervical HPV infections: influence of HPV type, duration of infection and previous and concomitant infection.

	Median time to clearance [1], months (inter-quartiles)	Multivariable analysis of the chance of clearance ²	
		Hazard ratio (95% CI)	p-value
16505 infections in 4793 women³			
10810 clearances			
HPV type			
Non-oncogenic type	8.26 (5.97–17.57)	1	-
HPV-16	17.11 (7.80–30.26)	0.81 (0.75–0.88)	<0.0001
HPV-18	11.84 (6.20–23.11)	0.93 (0.85–1.03)	0.1748
HPV-31	13.80 (6.43–28.89)	0.82 (0.74–0.90)	<0.0001
HPV-33	12.00 (6.20–21.90)	0.95 (0.84–1.08)	0.4557
HPV-45	11.48 (6.20–23.31)	0.93 (0.80–1.08)	0.3465
Other oncogenic type	11.77 (6.20–20.03)	0.96 (0.91–1.02)	0.1739
	<i><0.0001</i>	<i><0.0001</i>	
Duration of infection			
Transient	6.26 (5.70–8.16)	1	-
Less than 6MPI	11.02 (10.16–13.18)	0.40 (0.34–0.45)	<0.0001
6MPI	18.85 (12.66–34.52)	0.14 (0.13–0.14)	<0.0001
	<i><0.0001</i>	<i><0.0001</i>	
Previous cervical HPV infection⁴			
No	11.25 (6.03–18.79)	1	-
Yes (same HPV type)	13.64 (6.43–NE)	0.58 (0.52–0.64)	<0.0001
Yes (other HPV type[s])	11.84 (6.23–22.43)	0.72 (0.68–0.77)	<0.0001
	<i><0.0001</i>	<i><0.0001</i>	
Cervical HPV co-infection^{5, 6}			
No	-	1	-
Yes (at least 1 oncogenic HPV type)	-	1.08 (1.01–1.14)	0.0146
Yes (only non-oncogenic HPV types)	-	1.03 (0.93–1.15)	0.5501
	<i>Not done⁴</i>	<i>0.0473</i>	

¹ Time from first detection to first negative results

² Covariates were included in the multivariable analysis if they had a global p-value of <0.2 (except region which was always included); covariates were: region, smoking, age at first sexual intercourse, number of sexual partners during the past 12 months, history of Chlamydia trachomatis during the past 12 months, marital/partner status, previous pregnancy, use of hormones for contraception or other indication, use of intrauterine device, previous or concomitant HPV co-infections, previous or concomitant CIN1+. Refer to Table S8 for more detail.

³ Infections or clearances with a missing value for a covariate included in the analysis were excluded from the multivariable analysis.

⁴ Preceding the onset of the reference infection.

⁵ Following the onset of the reference infection and preceding its end.

⁶ Time-varying covariates: Kaplan-Meier analysis not done.

Values in italics show the log-rank p-value (for the median time to clearance) or the global p-value (for the multivariable analysis).

6MPI: 6-month persistent infection; HPV: human papillomavirus; NE: not estimated

doi: 10.1371/journal.pone.0079260.t004

FUTURE I study reported persistence of 12 months or more and the highest risk of progression to CIN2+ for HPV-16 and HPV-33 [22].

HPV-18 is the second most prevalent HPV type in ICC after HPV-16 [2,19]. The recent HERACLES/SCALE studies have suggested that high grade pre-cancerous lesions associated with HPV-18 are more likely to progress to cancer than lesions associated with any other HPV type [23], and a Markov model has also shown a higher risk of progression to later stages for HPV-18 [24]. Our results also suggest that the carcinogenicity of HPV-18 results from high rates of progression of HPV-18-

associated CIN3 to ICC, rather than from progression of HPV-18 infection to pre-cancerous lesions.

The risk of developing a CIN was increased by co-infection. Similarly, risk was increased by the presence of a separate CIN1+; this was true regardless of whether the CIN1+ lesion preceded the onset of the reference infection or whether it was concomitant with the reference infection. Some studies have shown that there is a higher chance of acquiring a new HPV type if already infected [25–27], and one study has shown that HPV-16 viral loads in lesions co-infected with other HPV types were higher than in lesions infected with HPV-16 alone [28]. However, other studies have shown that infections with

	No. 6MPI	Prevalence in 6MPI (%)	Risk of CIN3+ (HR)	Chance of clearance (HR)
Non-oncogenic	1443	20.9	1 (reference)	1 (reference)
HPV-16	956	13.9	26.8	0.81
HPV-18	417	6.0	6.0	0.93
HPV-31	449	6.5	9.8	0.82
HPV-33	210	3.0	25.0	0.95
HPV-45	153	2.2	6.9	0.93
Other oncogenic	3274	47.4	3.7	0.96

Figure 4. Summary according to HPV type of prevalence in 6MPI, risk of progression to CIN3+ lesion and chance of clearance. Dark-shaded boxes: high prevalence (>10%), high risk of progression (HR >20) or low chance of clearance (HR <0.85) Medium-shaded boxes: medium prevalence (5–10%), medium risk of progression (HR 5–20) or medium chance of clearance (0.85–<0.95)

Light-shaded boxes: low prevalence (<5%), low risk of progression (HR <5) or high chance of clearance (HR ≥0.95)

Definitions of high, medium and low prevalence, risk of progression and chance of clearance are arbitrary and are based on the results of the present study.

6MPI: 6-month persistent infection; CIN: cervical intraepithelial neoplasia; HPV: human papillomavirus; HR: hazard ratio.

doi: 10.1371/journal.pone.0079260.g004

different oncogenic HPV types occur independently of one another [29–31].

Consistent with the risk of progression to CIN, HPV-16 and HPV-31 had the least chance of being cleared, followed by HPV-33, HPV-18, HPV-45 and any other oncogenic type. HPV-16 and HPV-31 have been previously reported to have the lowest rates of clearance [32]. Previous infection diminished the chance of clearance but, unexpectedly, co-infection seemed to increase the chance. However, the observed beneficial effect of co-infection was relatively weak compared with the deleterious effect of previous infection. It is paradoxical that co-infection increased the risk of progression to a CIN but also increased the chance of clearance. There is no clear explanation for these findings.

Several behavioural determinants were associated with higher risk of progression from infection to lesion (tobacco exposure, previous pregnancy, use of hormones and age at first sexual intercourse) and lower chance of clearance of infection (marital/partner status). An increased risk of cervical abnormalities and/or cancer associated with these determinants has been shown in other studies [6–8].

The analyses had some strengths and limitations. We included only women with a confirmed HPV infection including 6MPI. The analysis therefore focused on factors that may influence the risk of progression from infection to lesion, and was not confounded by the risk of HPV acquisition. Another major strength was that the PATRICIA study included a large population with well-characterised virological and histological samples and high follow-up rates over 48 months. Although the study was multinational, involving women from many ethnic groups, all participants followed the same protocol. The high number of participants and length of follow-up allowed analysis of CIN3+ lesions, which are a better predictor of ICC than CIN2+ lesions [33]. Previous studies evaluating risk of progression have had a smaller sample size and studied a lower number of infections.

A limitation of the analysis is that misclassification of HPV infection below the threshold for detection by PCR (a false-negative result) might have overestimated rates of transient HPV infection and underestimated 6MPI. Therefore, analyses of clearance were done on subjects with two consecutive negative PCR results (“confirmed clearance”). However, a sensitivity analysis using a single negative PCR result gave

very similar results (data not shown), demonstrating that the risk of misclassification is low. As mentioned earlier, apparent clearance could actually represent inability to detect the infection. In addition, because pre-cancerous lesions may develop over an extended period, the duration of which is influenced by the HPV type the lesion is associated with, a follow-up of 48 months will not allow detection of all lesions. This may have led to underestimation of the progression rate of some HPV types. A further limitation is that many women started sexual activity before study enrolment and thus some previous HPV infections would not have been recorded. Finally, the study included only women aged 15–25 years, with six or fewer lifetime sexual partners and no history of immunosuppressive disease, limiting its generalizability; in particular, age may have an important influence on the rate of progression or clearance of HPV infection.

In conclusion, we have used data from the control arm of the large, well-controlled PATRICIA study to evaluate the natural history of progression of HPV infection to CIN lesion or to clearance according to individual HPV type. Importantly, we included CIN3, the immediate precursor lesion of cervical cancer. A better understanding of the natural mechanisms of progression to CIN lesions could contribute towards effective implementation of HPV testing as part of screening for early detection and prevention of cervical cancer, as recommended by recent US guidelines [34]. Infection with oncogenic HPV types increased the risk of development of CIN1+, CIN2+ or CIN3+, the highest risk being associated with HPV-16 and HPV-33, whilst infections with HPV types 16 and 31 had the lowest likelihood of being cleared. The risk of progression was increased as lesion severity increased, almost doubling from CIN1+ to CIN2+ and from CIN2+ to CIN3+ for HPV types 16, 31, 33 and 45. We found that previous or concomitant HPV infection or CIN1+ also increased the risk of progression to a lesion, suggesting that multiple HPV infections could influence progression. This finding is relevant to prevention of cervical cancer, and deserves further investigation.

Supporting Information

File S1. Supporting Files Table S1. List of Independent Ethics Committees/ Institutional Review Boards.

Table S2. Risk of progression of a 6-month persistent cervical HPV infection to a CIN1+ lesion associated with the same HPV type.

Table S3. Risk of progression of a 6-month persistent cervical HPV infection to a CIN2+ lesion associated with the same HPV type.

Table S4. Risk of progression of a 6-month persistent cervical HPV infection to a CIN3+ lesion associated with the same HPV type.

Table S5. Risk of progression of an HPV infection of any duration to a CIN1+ lesion associated with the same HPV type.

Table S6. Risk of progression of an HPV infection of any duration to a CIN2+ lesion associated with the same HPV type.

Table S7. Risk of progression of an HPV infection of any duration to a CIN3+ lesion associated with the same HPV type.

Table S8. Clearance and median duration of a cervical HPV infection. (DOCX)

File S2. Protocol and STROBE documents. (ZIP)

Acknowledgements

We thank all study participants and their families. We gratefully acknowledge the work of the central and local study co-ordinators, and staff members of the sites that participated in this study.

Contribution to statistical support was provided by D Rosillon and M-P David (GlaxoSmithKline vaccines, Wavre, Belgium), A Raillard, S Collas De Souza, M-Cecile Bozonnat (4 Clinics, Paris, France, Contract Research Organization on behalf of GlaxoSmithKline vaccines, Wavre, Belgium).

Writing support services were provided by M Greenacre PhD (An Sgriobhadair Ltd) on behalf of GlaxoSmithKline vaccines, Wavre, Belgium; editing and publication co-ordinating services were provided by J Andersson PhD (CROMSOURCE Ltd, UK) on behalf of GlaxoSmithKline vaccines, Wavre, Belgium, and publication co-ordinating services were provided by V Delpire (Words and Science, Brussels, Belgium) on behalf of GlaxoSmithKline vaccines, Wavre, Belgium.

The HPV PATRICIA Study Group: Collaborators

Principal investigators/co-investigators: *Australia* I Denham, S M Garland, A Mindel, S R Skinner. *Belgium* P De Sutter, W A J Poppe, W Tjalma. *Brazil* N S De Carvalho, P Naud, J C Teixeira. *Canada* F Y Aoki, F Diaz-Mitoma, M Dionne, L Ferguson, M Miller, K Papp, B Ramjattan, B Romanowski, P H Orr, R Somani. *Finland* D Apter, T Karppa, N Kudjoi, L Kyha-Österlund, M Lehtinen, K Lönnberg, T Lunnas, J Paavonen, J Palmroth, T Petaja, M Vilkki. *Germany* T Gent, T Grubert, W D Höpker, K Peters, K Schulze, TF Schwarz. *Mexico* J Salmerón. *Philippines* C Crisostomo, MR Del Rosario-Raymundo, JE Raymundo, M J Germar, G Limson, C Remollino, G Villanueva, S Villanueva, J D Zamora. *Spain* J Bajo-Arenas, J Bayas, M Campins, X Castellsagué, M Castro, C Centeno, ML Rodríguez de la Pinta, A Torné, J A Vidart. *Taiwan* S N Chow, M H Yu. *Thailand* S Angsuwathana, U Jaisamrarn. *UK* M Cruickshank, E A Hakim, H Kitchener, D Lewis, A Szarewski. *USA* R Ackerman, M Caldwell, C Chambers, A Chatterjee, L DeMars, L Downs, P Fine, J Hedrick, W Huh, T Klein, J Lalezari, S Lubner, M Martens, C Peterson, J Rosen, L Seidman, M Sperling, R Sperling, M Stager, J Stapleton, K Swenson, C Thoming, L Twigg, A Waldbaum, C M Wheeler.

Other Contributors

GlaxoSmithKline clinical study support

A Camier, B Colau, S Genevros, P Marius, N Martens, T Ouammou, M Rahier, B Spiessens, A Meurée, N Houard, F Dessy, A Tonglet, A S Vilain, C Van Hoof (Xpe Pharma), H Bhat (associate publication writer).

Laboratory contribution

E Alt, B Iskaros, A Limaye, R D Luff, M McNeeley, B Winkler (Quest Diagnostics Clinical Trials, Teterboro, NJ, USA). A

Molijn, W Quint, L Struijk, M Van de Sandt, L J Van Doorn (DDL Diagnostic Laboratory, Voorburg, The Netherlands).
Endpoint committee
N Kiviat, K P Klugman, P Nieminen.
Independent Data Monitoring Committee
C Bergeron, E Eisenstein, R Marks, T Nolan, S K Tay.
CERVARIX is a registered trademark of the GlaxoSmithKline group of companies.

Author Contributions

Wrote the manuscript: UJ XC SMG MRDRR PN J. Palmroth LB DR. Collected data for the trial and cared for the subjects: UJ

References

- Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer A et al. (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. *J Pathol* 189: 12–19. doi:10.1002/(SICI)1096-9896(199909)189:1. PubMed: 10451482.
- de Sanjose S, Quint WGV, Alemany L, Geraets DT, Klaustermeier JE et al. (2010) Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional survey. *Lancet Oncol* 11: 1048–1056. doi:10.1016/S1470-2045(10)70230-8. PubMed: 20952254.
- Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB et al. (2003) Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. *Am J Epidemiol* 157: 218–226. doi:10.1093/aje/kwf180. PubMed: 12543621.
- Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE et al. (1994) Persistence of type-specific human papillomavirus infection among cytologically normal women. *J Infect Dis* 169: 235–240. doi:10.1093/infdis/169.2.235. PubMed: 8106758.
- Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D et al. (2008) Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. *Am J Epidemiol* 168: 123–137. doi:10.1093/aje/kwn036. PubMed: 18483125.
- International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, Berrington de González A, et al. (2006) Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. *Int J Cancer* 118: 1481–1495.
- International Collaboration of Epidemiological Studies of Cervical Cancer (2007) Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. *Int J Cancer* 120: 885–891 PubMed: 17131323
- International Collaboration of Epidemiological Studies of Cervical Cancer. (2009) Cervical carcinoma and sexual behavior: collaborative reanalysis of individual data on 15,461 women with cervical carcinoma and 29,164 women without cervical carcinoma from 21 epidemiological studies. *Cancer Epidemiol Biomarkers Prev* 18: 1060–1069
- Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA (2009) Risk of human papillomavirus-associated cancers among persons with AIDS. *J Natl Cancer Inst* 101: 1120–1130. PubMed: 19648510.
- Smith JS, Muñoz N, Herrero R, Eluf-Neto J, Ngelangel C et al. (2002) Evidence for *Chlamydia trachomatis* as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. *J Infect Dis* 185: 324–331. doi:10.1086/338569. PubMed: 11807714.
- Smith JS, Herrero R, Bosetti C, Muñoz N, Bosch FX et al. (2002b) Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. *J Natl Cancer Inst* 94: 1604–1613. doi:10.1093/jnci/94.21.1604. PubMed: 12419786.
- Castle PE, Schiffman M, Wheeler CM, Solomon D (2009) Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. *Obstet Gynecol* 113: 18–25. PubMed: 19104355.
- Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J et al. (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. *Lancet* 369: 2161–2170. doi:10.1016/S0140-6736(07)60946-5. PubMed: 17602732.
- Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow S-N et al. (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. *Lancet* 374: 301–314. doi:10.1016/S0140-6736(09)61248-4. PubMed: 19586656.
- van Doorn L-J, Molijn A, Kleter B, Quint W, Colau B (2006) Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. *J Clin Microbiol* 44: 3292–3298. doi:10.1128/JCM.00539-06. PubMed: 16954263.
- Roset Bahmanyar E, Paavonen J, Naud P, Salmerón J, Chow SN et al. (2012) Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women enrolled in the multinational PATRICIA trial. *Gynecol Oncol* 127: 440–450. doi:10.1016/j.ygyno.2012.08.033. PubMed: 22940493.
- Lin DY, Wei LJ (1989) The robust inference for the Cox proportional hazards model. *J American Statistical Assoc* 84: 1074–1078. doi:10.1080/01621459.1989.10478874.
- Zeger SL, Liang KY (1986) Longitudinal data analysis for discrete and continuous outcomes. *Biometrics* 42: 121–130. doi:10.2307/2531248. PubMed: 3719049.
- Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WGV et al. (2009) Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. *J Natl Cancer Inst* 101: 475–487. doi:10.1093/jnci/djn510. PubMed: 19318628.
- Schiffman M, Herrero R, DeSalle R, Hildesheim A, Wacholder S et al. (2005) The carcinogenicity of human papillomavirus types reflects viral evolution. *Virology* 337: 76–84. doi:10.1016/j.virol.2005.04.002. PubMed: 15914222.
- Bulkman NW, Bleeker MCG, Berkhof J, Voorhorst FJ, Snijders PJF et al. (2005) Prevalence of types 16 and 33 is increased in high-risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 or worse. *Int J Cancer* 117: 177–191. doi:10.1002/ijc.21210. PubMed: 15900579.
- Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM et al.; FUTURE I Investigators (2011) Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. *Cancer Epidemiol Biomarkers Prev* 20: 287–296 doi:10.1158/1055-9965.EPI-10-0791. PubMed: 21300618.
- Tjalma WA, Fiander A, Reich O, Powell N, Nowakowski AM et al. (2013) Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. *Int J Cancer*, 132: 854–67. doi:10.1002/ijc.27713. Epub ahead of print PubMed: 22752992.
- Jit M, Gay N, Soldan K, Hong Choi Y, Edmunds WJ (2010) Estimating progression rates for human papillomavirus infection from epidemiological data. *Med Decis Making* 30: 84–98. doi:10.1177/0272989X09336140. PubMed: 19525483.
- Liaw KL, Hildesheim A, Burk RD, Gravitt P, Wacholder S et al. (2001) A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. *J Infect Dis* 183: 8–15. doi:10.1086/317638. PubMed: 11087198.
- Rousseau MC, Pereira JS, Prado JC, Villa LL, Rohan TE et al. (2001) Cervical coinfection with human papillomavirus (HPV) types as a

- predictor of acquisition and persistence of HPV infection. *J Infect Dis* 184: 1508–1517. doi:10.1086/324579. PubMed: 11740725.
27. Mendez F, Munoz N, Posso H, Molano M, Moreno V et al. (2005) Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines. *J Infect Dis* 192: 1158–1165. doi:10.1086/444391. PubMed: 16136457.
 28. Weissenborn SJ, Funke AM, Hellmich M, Mallmann P, Fuchs PG et al. (2003) Oncogenic human papillomavirus DNA loads in human immunodeficiency virus-positive women with high-grade cervical lesions are strongly elevated. *J Clin Microbiol* 41: 2763–2767. doi: 10.1128/JCM.41.6.2763-2767.2003. PubMed: 12791926.
 29. Vaccarella S, Franceschi S, Snijders PJ, Herrero R, Meijer CJ et al. (2010) Concurrent infection with multiple human papillomavirus types: pooled analysis of the IARC HPV Prevalence Surveys. *Cancer Epidemiol Biomarkers Prev* 19: 503–510. doi: 10.1158/1055-9965.EPI-09-0983. PubMed: 20142247.
 30. Carozzi F, Ronco G, Gillio-Tos A, De Marco L, Del Mistro D et al. (2012) Concurrent infections with multiple human papillomavirus (HPV) types in the New Technologies for Cervical Cancer Screening (NTCC) Working Group. *Eur J Cancer* 48: 1633–1637. doi:10.1016/j.ejca.2011.10.010. PubMed: 22088483.
 31. Vaccarella S, Franceschi S, Herrero R, Schiffman M, Rodriguez Ac, et al. (2011) Clustering of multiple human papillomavirus infections in women from a population-based study in Guanacaste, Costa Rica. *J Infect Dis* 204: 385–390
 32. Bulkman NW, Berkhof J, Bulk S, Bleeker MC, van Kemenade FJ et al. (2007) High-risk HPV type-specific clearance rates in cervical screening. *Br J Cancer* 96: 1419–1424. PubMed: 17342094.
 33. Lehtinen M, Paavonen J, Wheeler CM, Jaisamram U, Garland SM et al. (2012) Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. *Lancet Oncol* 13: 89–99. doi:10.1016/S1470-2045(11)70286-8. PubMed: 22075171.
 34. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL et al. (2012) American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. *Am J Clin Pathol* 137: 516–542. doi:10.1309/AJCPD94EVRSJCG. PubMed: 22431528.